Relevant publications HEIM

Relevant publications HEIM

1.         Favreau, Mérédis; Menu, Eline, Gaublomme Djoere, Vanderkerken, Karin; Faict, Sylvia; Maes, Ken; De Bruyne, Elke; Govindarajan Srinath; Drennan Michael; Van Calenbergh Serge; Leleu Xavier; Zabeau Lennart; Tavernier Jan; Venken, Koen Elewaut, Dirk; Leptin receptor antagonism of iNKT cell function: a strategy to combat multiple myeloma, Leukemia, 2017 May 11. doi: 10.1038/leu.2017.146

2.         De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter J, Schots H, Vanderkerken K, Van Valckenborgh E, Tumor-associated macrophage mediated survival of myeloma cells through STAT3 activation. J of Pathology, 2017; 241(4):534-546.

3.         De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Letters. 2016 July 10;377(1):17-24.

4.         Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen H, Nyegaard M, Jernberg-Wiklund H, Schots H, Vanderkerken K,De Bruyne E. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget. 2014 Nov 30;22(5):11193-11208.

5.         Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma, Oncotarget. 2014 Feb 20;6(5):3319-34.

6.         Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014 July 24;4(124):555–566.